In Brief: Cardiac Pacemakers' Endotak
This article was originally published in The Gray Sheet
Executive Summary
Cardiac Pacemakers' Endotak: Guidant subsidiary launches Endotak Model 115 single lead defibrillation system to U.S. market. The Model 115 is 70 cm in length, shorter than currently offered CPI leads, which are 100 cm. One potential use for the short lead is with pectorally implanted automatic implantable cardioverter defibrillator products. A premarket approval application supplement for Guidant's Ventak PRx III AICD, which can be implanted pectorally, was approved by FDA in early May ("The Gray Sheet" May 8, In Brief)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.